Integrating Neural Networks with a Quantum Simulator for State Reconstruction

We demonstrate quantum many-body state reconstruction from experimental data generated by a programmable quantum simulator, by means of a neural network model incorporating known experimental errors. Specifically, we extract restricted Boltzmann machine (RBM) wavefunctions from data produced by a Rydberg quantum simulator with eight and nine atoms in a single measurement basis, and apply a novel regularization technique to mitigate the effects of measurement errors in the training data. Reconstructions of modest complexity are able to capture one- and two-body observables not accessible to experimentalists, as well as more sophisticated observables such as the R\'enyi mutual information. Our results open the door to integration of machine learning architectures with intermediate-scale quantum hardware.Comment: 15 pages, 13 figure

Integrating Neural Networks with a Quantum Simulator for State Reconstruction

We demonstrate quantum many-body state reconstruction from experimental data generated by a programmable quantum simulator by means of a neural-network model incorporating known experimental errors. Specifically, we extract restricted Boltzmann machine wave functions from data produced by a Rydberg quantum simulator with eight and nine atoms in a single measurement basis and apply a novel regularization technique to mitigate the effects of measurement errors in the training data. Reconstructions of modest complexity are able to capture one- and two-body observables not accessible to experimentalists, as well as more sophisticated observables such as the Rényi mutual information. Our results open the door to integration of machine learning architectures with intermediate-scale quantum hardware

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Background: Short-term treatment for people with type 2 diabetes using a low dose of the selective endothelin A receptor antagonist atrasentan reduces albuminuria without causing significant sodium retention. We report the long-term effects of treatment with atrasentan on major renal outcomes. Methods: We did this double-blind, randomised, placebo-controlled trial at 689 sites in 41 countries. We enrolled adults aged 18–85 years with type 2 diabetes, estimated glomerular filtration rate (eGFR)25–75 mL/min per 1·73 m 2 of body surface area, and a urine albumin-to-creatinine ratio (UACR)of 300–5000 mg/g who had received maximum labelled or tolerated renin–angiotensin system inhibition for at least 4 weeks. Participants were given atrasentan 0·75 mg orally daily during an enrichment period before random group assignment. Those with a UACR decrease of at least 30% with no substantial fluid retention during the enrichment period (responders)were included in the double-blind treatment period. Responders were randomly assigned to receive either atrasentan 0·75 mg orally daily or placebo. All patients and investigators were masked to treatment assignment. The primary endpoint was a composite of doubling of serum creatinine (sustained for ≥30 days)or end-stage kidney disease (eGFR <15 mL/min per 1·73 m 2 sustained for ≥90 days, chronic dialysis for ≥90 days, kidney transplantation, or death from kidney failure)in the intention-to-treat population of all responders. Safety was assessed in all patients who received at least one dose of their assigned study treatment. The study is registered with ClinicalTrials.gov, number NCT01858532. Findings: Between May 17, 2013, and July 13, 2017, 11 087 patients were screened; 5117 entered the enrichment period, and 4711 completed the enrichment period. Of these, 2648 patients were responders and were randomly assigned to the atrasentan group (n=1325)or placebo group (n=1323). Median follow-up was 2·2 years (IQR 1·4–2·9). 79 (6·0%)of 1325 patients in the atrasentan group and 105 (7·9%)of 1323 in the placebo group had a primary composite renal endpoint event (hazard ratio [HR]0·65 [95% CI 0·49–0·88]; p=0·0047). Fluid retention and anaemia adverse events, which have been previously attributed to endothelin receptor antagonists, were more frequent in the atrasentan group than in the placebo group. Hospital admission for heart failure occurred in 47 (3·5%)of 1325 patients in the atrasentan group and 34 (2·6%)of 1323 patients in the placebo group (HR 1·33 [95% CI 0·85–2·07]; p=0·208). 58 (4·4%)patients in the atrasentan group and 52 (3·9%)in the placebo group died (HR 1·09 [95% CI 0·75–1·59]; p=0·65). Interpretation: Atrasentan reduced the risk of renal events in patients with diabetes and chronic kidney disease who were selected to optimise efficacy and safety. These data support a potential role for selective endothelin receptor antagonists in protecting renal function in patients with type 2 diabetes at high risk of developing end-stage kidney disease. Funding: AbbVie

Deregulating School Aid in California: How 10 Districts Responded to Fiscal Flexibility, 2009-2010

Based on interviews, examines districts' responses to provisions relaxing spending restrictions on categorical funding, their consequences, factors that shaped budget decisions and any benefits, the role of federal stimulus funds, and policy implications

Integrating Neural Networks with a Quantum Simulator for State Reconstruction

© 2019 American Physical Society. We demonstrate quantum many-body state reconstruction from experimental data generated by a programmable quantum simulator by means of a neural-network model incorporating known experimental errors. Specifically, we extract restricted Boltzmann machine wave functions from data produced by a Rydberg quantum simulator with eight and nine atoms in a single measurement basis and apply a novel regularization technique to mitigate the effects of measurement errors in the training data. Reconstructions of modest complexity are able to capture one- and two-body observables not accessible to experimentalists, as well as more sophisticated observables such as the Rényi mutual information. Our results open the door to integration of machine learning architectures with intermediate-scale quantum hardware